ArticleJournal of cancer research and clinical oncology2025
Real-world evidence on the additional cancer risk reduction of ezetimibe: a 10-year nationwide retrospective cohort study emulating a target trial.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- BMI-Based and Clinical-Obesity Trajectories and Incident Cardiovascular Disease: A Prospective UK Biobank Study.Journal of clinical medicine · 2026Article
- Article
- Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study.Frontiers in endocrinology · 2026Article
- Joint associations of cardiovascular polygenic risk and a health-related risk profile with incident cardiovascular disease among adults with depression: a UK Biobank study.Frontiers in endocrinology · 2026Article
- Atorvastatin as a pleiotropic anticancer agent: mechanisms, evidence, and therapeutic repurposing potential.Frontiers in immunology · 2026Review
- Association of organ dysfunction trajectories and major adverse cardiovascular events using clinical obesity in UK Biobank.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLipid-lowering therapies, particularly statins, have been associated with a reduced risk of cancer. However, the potential additional protective effects of ezetimibe remain unclear in real-world settings. This study investigated whether statin/ezetimibe combination therapy provided further cancer risk reduction beyond statin monotherapy.
methodsA nationwide retrospective cohort study was conducted using the Korean National Health Insurance Service database. Patients with dyslipidemia (total cholesterol ≥ 240 mg/dL) diagnosed between 2004 and 2009 were included and categorized into statin users, statin/ezetimibe users, and nonusers. Cancer incidence over 5- and 10-year follow-up periods was assessed using Cox proportional hazards models adjusted for demographic, clinical, and lifestyle factors. Inverse probability of treatment weighting (IPTW) was applied to account for potential confounders, and sensitivity analyses were performed to assess the stability of the findings.
resultsAmong 68,353 patients, 9,267 were statin users, 383 were statin/ezetimibe users, and 58,703 were nonusers. Statin users exhibited a reduced cancer risk at 5 years (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI] 0.80–0.89) and 10 years (aHR, 0.91; 95% CI 0.87–0.94). Statin/ezetimibe users demonstrated a greater reduction in cancer risk (5 years: aHR, 0.30; 95% CI 0.28–0.32; 10 years: aHR, 0.70; 95% CI 0.67–0.73). Trend analysis confirmed an incremental trend in cancer risk reduction with increasing lipid-lowering therapy intensity (P for trend < 0.001).
conclusionThis real-world study suggests that ezetimibe, when combined with statins, is associated with additional cancer risk reduction beyond statin monotherapy, as observed across both overall and direct comparative analyses. Further research is warranted to confirm the independent effects of ezetimibe and its potential role in cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.